IDEXX LABORATORIES INC /DE — Director's Dealing 2020

Nov 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2020-11-04

Reporting Person: MCKEON BRIAN P (Executive VP & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-04	Common Stock	M	36216	$79.54	Acquired	60916	Direct
2020-11-04	Common Stock	S	1400	$467.0142	Disposed	59516	Direct
2020-11-04	Common Stock	S	6338	$467.9662	Disposed	53178	Direct
2020-11-04	Common Stock	S	9617	$469.0944	Disposed	43561	Direct
2020-11-04	Common Stock	S	2850	$469.7968	Disposed	40711	Direct
2020-11-04	Common Stock	S	2493	$471.0224	Disposed	38218	Direct
2020-11-04	Common Stock	S	1107	$472.1960	Disposed	37111	Direct
2020-11-04	Common Stock	S	2407	$473.0377	Disposed	34704	Direct
2020-11-04	Common Stock	S	244	$473.9679	Disposed	34460	Direct
2020-11-04	Common Stock	S	3474	$475.2004	Disposed	30986	Direct
2020-11-04	Common Stock	S	3596	$476.0122	Disposed	27390	Direct
2020-11-04	Common Stock	S	390	$477.0165	Disposed	27000	Direct
2020-11-04	Common Stock	S	1534	$479.6945	Disposed	25466	Direct
2020-11-04	Common Stock	S	566	$480.3068	Disposed	24900	Direct
2020-11-04	Common Stock	S	200	$481.26	Disposed	24700	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-04	Non-Qualified Stock Option (right-to-buy)	$79.54	M	36216	Disposed	2025-02-13	Common Stock (36216)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	28050	Indirect

Footnotes

F1: Includes 18 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2020 and excludes 28,050 shares previously owned directly which were contributed to the Estony McKeon Family, LLC on August 21, 2020.

F2: Represents the weighted average price of the shares sold ranging from a low of $466.36 to a high of $467.31 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $467.38 to a high of $468.38 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $468.39 to a high of $469.39 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Represents the weighted average price of the shares sold ranging from a low of $469.40 to a high of $470.37 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F6: Represents the weighted average price of the shares sold ranging from a low of $470.43 to a high of $471.43 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F7: Represents the weighted average price of the shares sold ranging from a low of $471.44 to a high of $472.34 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F8: Represents the weighted average price of the shares sold ranging from a low of $472.46 to a high of $473.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F9: Represents the weighted average price of the shares sold ranging from a low of $473.5275 to a high of $474.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F10: Represents the weighted average price of the shares sold ranging from a low of $474.63 to a high of $475.63 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F11: Represents the weighted average price of the shares sold ranging from a low of $475.70 to a high of $476.51 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F12: Represents the weighted average price of the shares sold ranging from a low of $476.785 to a high of $477.25 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F13: Represents the weighted average price of the shares sold ranging from a low of $479.14 to a high of $480.135 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F14: Represents the weighted average price of the shares sold ranging from a low of $480.17 to a high of $480.53 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F15: Grant of option to buy 18,108 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F16: Not applicable.